clinical trial · NCT07093801
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Metastatic Castration Resistant Prostate Cancer
brief summary
This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.
started
Jul 30, 2025
primary completion
Mar 30, 2029
completion
Mar 30, 2029
last updated
Feb 20, 2026
official title
Real-world Experience of Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, National, Multicenter, Prospective Cohort Study (PLU4REAL).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol